+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Oxidative stress and mitochondrial dysfunction are the underlying events of dopaminergic neurodegeneration in homocysteine rat model of Parkinson's disease



Oxidative stress and mitochondrial dysfunction are the underlying events of dopaminergic neurodegeneration in homocysteine rat model of Parkinson's disease



Neurochemistry International 101: 48-55



Homocysteine (Hcy) when injected intranigrally in rat caused parkinsonian behavioural phenotypes and loss of nigral dopaminergic neurons but the underlying mechanisms of neurotoxicity remains elusive. In the present study, we focused on oxidative stress as one of the mechanisms of neurotoxicity in Hcy-induced hemiparkinsonian rat model. Unilateral intranigral infusion of Hcy (1.0 μmol in 2 μl) caused inhibition of mitochondrial complex-I activity, decrease in the level of striatal dopamine, loss of midbrain dopaminergic neurons, and motor abnormalities. Hcy caused oxidative stress in the nigrostriatal pathway, with increase in generation of hydroxyl radicals, depletion in the level of reduced glutathione and enhanced activity of antioxidant enzymes (superoxide dismutase and catalase). Our results provided the evidence of critical involvement of oxidative stress as one of the mechanisms underlying Hcy-induced dopaminergic neurotoxicity in nigrostriatal pathway. As oxidative stress is one of the prime mechanisms of neurodegeneration in different animal models of Parkinson's disease, and since Hcy caused equivalent parkinsonian pathologies in rat model, the present study proclaims Hcy-induced rat model as a viable rodent model of Parkinson's disease.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058488958

Download citation: RISBibTeXText

PMID: 27732886

DOI: 10.1016/j.neuint.2016.10.001


Related references

Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson's Disease. Journal of Neurochemistry 141(5): 766-782, 2017

Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease. Frontiers in Neuroscience 10: 321, 2016

Oxidative stress mechanisms underlying Parkinson's disease-associated neurodegeneration in C. elegans. International Journal of Molecular Sciences 14(11): 23103-23128, 2013

LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. Neurobiology of Disease 40(1): 73-81, 2010

CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease. Journal of Neuroinflammation 8: 154, 2011

Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model. Neuroscience Letters 521(1): 15-19, 2012

Antimicrobial Peptide, Lumbricusin, Ameliorates Motor Dysfunction and Dopaminergic Neurodegeneration in a Mouse Model of Parkinson's Disease. Journal of Microbiology and Biotechnology 25(10): 1640-1647, 2015

Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Neurochemical Research 33(3): 589-597, 2008

Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Progress in Neurobiology 106-107: 17-32, 2014

Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiology of Disease 51: 35-42, 2013

Loss of PINK1 enhances neurodegeneration in a mouse model of Parkinson's disease triggered by mitochondrial stress. Neuropharmacology 77: 350-357, 2014

Iron induced oxidative stress and mitochondrial dysfunction: Relevance to Parkinson's disease. Brain Research 627(2): 349-353, 1993

S21 Neuromelanin And Its Interaction With Iron As A Potential Risk Factor For Dopaminergic Neurodegeneration Underlying Parkinson??S Disease. Behavioural Pharmacology 17(5-6): 541, 2006

Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Neurotoxicity Research 5(1-2): 35-44, 2003

Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease. Drug Design Development and Therapy 11: 797-810, 2017